ArticleFASEB bioAdvances2026
Growth Hormone Reverses Cisplatin-Induced Ovarian Reserve Depletion in Mice: Transcriptomic Elucidation of Mitochondrial Metabolic Reprogramming and Protein Synthesis Regulation.
Article in FASEB bioAdvances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diminished ovarian reserve (DOR) presents a formidable challenge for assisted reproduction technology, as affected patients typically exhibit reduced oocytes and embryos during in vitro fertilization and embryo transfer (IVF-ET), which may ultimately lead to compromised clinical pregnancy rate. Although growth hormone (GH) supplementation has shown clinical efficacy in improving the outcomes of IVF-ET, the precise molecular mechanisms underlying its ability to enhance ovarian reserve have remained poorly characterized. In this study, a cisplatin-induced DOR mice model was established via intraperitoneal cisplatin administration. GH was subsequently evaluated at four dose levels over a 21-day intervention period. Comprehensive assessments included quantitative follicular histomorphometry, serum hormone profiling, and whole-transcriptome analysis of ovarian tissue. GH treatment significantly increased the number of primary and secondary follicles in a dose-dependent manner (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.